Health Update: Panacea for diabetes and obesity approved in India!

 | 
aa

There is good news for millions of Indians who are struggling with diabetes and obesity. A drug which is considered a 'blockbuster' drug in the world of diabetes and weight loss has been approved to be launched in India.

aa

There is good news for people suffering from diabetes and obesity in India. The blockbuster drug Tirzeptide made by the American pharmaceutical company Eli Lilly has been approved to be launched in India. This drug is considered effective in type 2 diabetes and weight loss.

An expert committee of India's drug regulator, Central Drugs Standard Control Organization (CDSCO), has approved the import and marketing of this drug. However, this news is accompanied by a small disappointment. It may take some time for the drug to reach patients. According to Eli Lilly sources, the company still has to assess the status of the global supply chain of the drug. It is likely that the drug can be launched in India only next year. There is a lot of demand for this drug in the US as well, due to which shortages are still being seen in many doses.

The results of the studies are very good.

Clinical trials conducted in the US and many other countries have shown very positive results for Tirzeptide. In these trials, it was found that this drug is not only effective in controlling type 2 diabetes, but it can also reduce the weight of obese people to a great extent. In some cases, the body weight of the patients decreased by 15 to 20 percent.

Obesity and Diabetes in India: A Serious Problem

Diabetes and obesity have become a serious problem in India. Every year millions of people are falling prey to these diseases. In such a situation, drugs like Tirzeptide bring a new hope for people suffering from diabetes and obesity. However, this drug will be imported now and its price may be a little high in the beginning. But, it is expected that in future, if the production of this drug starts in India itself, its price may come down and it will also be accessible to common people.